Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE Detection rate and localization of prostate cancer recurrence using <sup>68</sup>Ga-PSMA-11 PET/MRI in patients with low PSA values ≤ 0.5 ng/ml. 31375566 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE To review the literature to determine the sensitivity and specificity of gallium-68 prostate-specific membrane antigen (<sup>68</sup> Ga-PSMA) positron-emission tomography (PET) for detecting pelvic lymph node metastases in patients with primary prostate cancer (PCa), and the positive predictive value in patients with biochemical recurrence (BCR) after initial curative treatment, and, in addition, to determine the detection rate and management impact of <sup>68</sup> Ga-PSMA PET in patients with BCR after radical prostatectomy (RP). 31680398 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE Incidental Detection of Pleomorphic Sarcoma on 68Ga-PSMA PET/CT in a Patient With Prostate Cancer. 31490315 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE GCPII inhibitors with high affinity for this protein have been developed as prostate imaging and radiochemical therapies for prostate cancer. 31730793 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer. 31840521 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE Thus, we suggest clinical use of copper labeled PSMA-CA003 for diagnostics and radiotherapy of prostate cancer. 31541034 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE The typical and predictable patterns of spread in prostate cancer are still more prevalent, such as spread to pelvic lymph nodes and bone metastasis, but different patterns of disease spread are becoming more commonly recognized with higher reliability because PSMA imaging allows detection of more typical and atypical lesions than conventional imaging. 30620699 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE Detection of Unusual Peritoneal Metastases of Prostate Cancer With 68Ga-Prostate-Specific Membrane Antigen PET/CT. 31789914 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE In this study we evaluated the diagnostic accuracy of <sup>68</sup>Ga prostate specific membrane antigen positron emission tomography/computerized tomography for detecting lymph node metastasis in patients with intermediate-high risk prostate cancer. 31487220 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 GeneticVariation disease BEFREE In this retrospective analysis, 116 patients who underwent <sup>68</sup>Ga-PSMA-11 PET/CT or MRI scans for staging of their intermediate or high-risk prostate cancer between April 2016 and May 2018 were included. 31802175 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and its Role in Salvage Lymph Node Dissection. 30929322 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE Imaging of Prostate Cancer Recurrence in the Vas Deferens With 68Ga-PSMA PET/CT. 31789910 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE Currently, the use of prostate-specific membrane antigen (PSMA)-targeted radiotracers, e.g., <sup>99m</sup>Tc-labelled PSMA tracer analogues for radioguided surgery, is revolutionising prostate cancer surgery. 31481575 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE A prostate-specific membrane antigen (PSMA)-targeting ligand, armed with both an organotrifluoroborate and a metal-chelator (DOTA), was designed to optionally afford <sup>18</sup> F-, <sup>64</sup> Cu- or <sup>177</sup> Lu-labeled products that were injected into mice bearing prostate cancer (LNCaP) xenografts. 31621172 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE Ga-PSMA PET-CT allows accurate detection of lymphnodal metastases in patients with intermediate-risk and high-risk prostate cancer prior to definitive surgical treatment. 31714366 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE We developed prostate-specific membrane antigen (PSMA)-targeted low-molecular-weight (LMW) agents for <sup>212</sup>Pb-based TRT of patients with prostate cancer (PC) by evaluating the matching γ-emitting surrogate, <sup>203</sup>Pb. 31253744 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE We collected <sup>68</sup>Ga-PSMA-11 PET/CT images from 193 patients with metastatic PC at three medical centers. 31813050 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE The present study is based on a retrospective analysis of Gallium-68 (<sup>68</sup>Ga)-labelled prostate-specific membrane antigen (<sup>68</sup>Ga-PSMA I&T) PET/CT performed in newly diagnosed, treatment-naïve prostate cancer (PCa) patients prior to definitive treatment. 31529265 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE Modelling the internalisation process of prostate cancer cells for PSMA-specific ligands. 31260881 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE Ga-PSMA PET/CT has emerged as a highly promising diagnostic method for the evaluation of prostate cancer. 31348089 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE Dual-time point PET/CT scanning with [<sup>68</sup>Ga]Ga-PSMA-11 in the diagnosis of prostate cancer (PC) has been advanced as a method to increase detection of PC lesions, particularly at early stages of biochemical recurrence and as a potential means to aid the discrimination between benign and pathological prostate-specific membrane antigen (PSMA) uptake. 31628514 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE PSMA PET/CT should be considered to monitor PCa response to chemotherapy to detect early relapse, regardless of prostate-specific antigen levels, increasing the chances of finding low-volume oligoprogressive disease. 31693605 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 Biomarker disease BEFREE Prospective Evaluation of PSMA-Targeted <sup>18</sup>F-DCFPyL PET/CT in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer. 31201249 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 GeneticVariation disease BEFREE A total of 63 patients diagnosed with PCa who underwent (<sup>68</sup>Ga)PSMA 11 PET/CT between April 2019 and June 2019 and who had 5th minute and 1st and 2nd hour images were included in the study. 31808135 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.400 GeneticVariation disease BEFREE The aim of this study was to assess the added value of <sup>68</sup>Ga-PSMA-11 PET in predicting lymph node metastasis in men with intermediate- or high-risk prostate cancer. 31522272 2020